Seeking Alpha

Nektar Therapeutics (NKTR): Q4 EPS of -$0.24 may not be comparable with consensus of -$0.16....

Nektar Therapeutics (NKTR): Q4 EPS of -$0.24 may not be comparable with consensus of -$0.16. Revenue of $45.3M (+16% Y/Y) beats by $3.8M. Shares +2.7% AH. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)